These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 15618590)
41. Philanthropy and Advocacy-Led Development of Gene Therapies and Drugs for Alpha-1 Antitrypsin Deficiency. Quach JM; Campbell R; Walsh J Hum Gene Ther; 2015 Dec; 26(12):783-5. PubMed ID: 26636478 [No Abstract] [Full Text] [Related]
42. [RAPID study: the first time the value of substitution therapy is verified]. MMW Fortschr Med; 2016 Jun; 158(12):68-9. PubMed ID: 27462663 [No Abstract] [Full Text] [Related]
43. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Nita I; Hollander C; Westin U; Janciauskiene SM Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545 [TBL] [Abstract][Full Text] [Related]
44. Autophagic disposal of the aggregation-prone protein that causes liver inflammation and carcinogenesis in alpha-1-antitrypsin deficiency. Perlmutter DH Cell Death Differ; 2009 Jan; 16(1):39-45. PubMed ID: 18617899 [TBL] [Abstract][Full Text] [Related]
45. Comment: Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency. Gemberling JH; Finnerty MA Ann Pharmacother; 2006 Apr; 40(4):786-7. PubMed ID: 16537818 [No Abstract] [Full Text] [Related]
46. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Chan ED; Kaminska AM; Gill W; Chmura K; Feldman NE; Bai X; Floyd CM; Fulton KE; Huitt GA; Strand MJ; Iseman MD; Shapiro L Scand J Infect Dis; 2007; 39(8):690-6. PubMed ID: 17654345 [TBL] [Abstract][Full Text] [Related]
48. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot. Bagoly Z; Haramura G; Muszbek L Thromb Haemost; 2007 Aug; 98(2):359-67. PubMed ID: 17721618 [TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS; Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352 [TBL] [Abstract][Full Text] [Related]
50. Exhaled nitric oxide levels in alpha-1-antitrypsin PiMZ subjects. Malerba M; Ragnoli B; Radaeli A J Intern Med; 2009 Mar; 265(3):382-7. PubMed ID: 19019191 [TBL] [Abstract][Full Text] [Related]
51. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma--results from the ALA-ACRC low-dose theophylline trial. Eden E; Holbrook JT; Brantly ML; Turino GM; Wise RA J Asthma; 2007 Oct; 44(8):605-8. PubMed ID: 17943569 [TBL] [Abstract][Full Text] [Related]
52. Cytotoxic concentrations of alpha-defensins in the lungs of individuals with alpha 1-antitrypsin deficiency and moderate to severe lung disease. Wencker M; Brantly ML Cytokine; 2005 Oct; 32(1):1-6. PubMed ID: 16137891 [TBL] [Abstract][Full Text] [Related]
53. Elevation of circulating thrombin-antithrombin III complex and fibrin degradation products in urticaria: a laboratory finding unrelated to intravascular coagulopathy. Fujii K; Usuki A; Kan-No Y; Ohgou N J Dermatol; 2008 May; 35(5):308-10. PubMed ID: 18477235 [No Abstract] [Full Text] [Related]
54. Plasma levels of alpha1-antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe alpha1-antitrypsin deficiency. Hollander C; Westin U; Wallmark A; Piitulainen E; Sveger T; Janciauskiene SM BMC Pulm Med; 2007 Jan; 7():1. PubMed ID: 17261175 [TBL] [Abstract][Full Text] [Related]
55. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro. Geraghty P; Rogan MP; Greene CM; Brantly ML; O'Neill SJ; Taggart CC; McElvaney NG Thorax; 2008 Jul; 63(7):621-6. PubMed ID: 18250185 [TBL] [Abstract][Full Text] [Related]
56. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464 [TBL] [Abstract][Full Text] [Related]
57. Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants. Ljujic M; Topic A; Divac A; Nikolic A; Petrovic-Stanojevic N; Surlan M; Mitic-Milikic M; Radojkovic D Transl Res; 2008 May; 151(5):255-9. PubMed ID: 18433707 [TBL] [Abstract][Full Text] [Related]
58. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Köhnlein T; Welte T Am J Med; 2008 Jan; 121(1):3-9. PubMed ID: 18187064 [TBL] [Abstract][Full Text] [Related]